F-1: MEDI Group Faces Financial Headwinds Ahead of Nasdaq IPO

MEDI Group Limited, a Hong Kong-based beauty and personal care service provider, is pursuing a Nasdaq IPO amidst declining revenues, negative operating cash flows, and a 'going concern' warning from its auditors.

Summary

• MEDI Group Limited, a Cayman Islands holding company, operates medical cosmetology and traditional beauty services in Hong Kong through its subsidiary, Grand Century Holding Company Limited (GCHL).
• The company is offering $15,000,000 (3,333,333 Class A Ordinary Shares) in an initial public offering, with an estimated price range of $4.00 to $5.00 per share.
• Existing shareholders are also offering 4,272,222 Class A Ordinary Shares for resale, from which the company will not receive any proceeds.
• Revenues decreased by 15.7% to $3.25 million for the six months ended December 31, 2024, from $3.86 million in the prior year period.
• Net income for the six months ended December 31, 2024, increased by 9.6% to $1 million, from $0.9 million in the prior year period.
• For the year ended June 30, 2024, revenues decreased by 24% to $6.11 million from $8.02 million in the prior year.
• Net income for the year ended June 30, 2024, decreased by 68% to $0.61 million from $1.90 million in the prior year, primarily due to increased audit fees and staff costs related to the offering.
• The company reported negative operating cash flows of $611,480 for the six months ended December 31, 2024, and $1,031,834 for the year ended June 30, 2024.
• Working capital deficits were $8,313,163 as of December 31, 2024, and $9,029,519 as of June 30, 2024.
• Auditors have expressed 'substantial doubt' about the company's ability to continue as a going concern.
• The company plans to close its Yuen Long shop by September 30, 2025, due to customer migration to mainland China service providers.
• Proceeds from the IPO will be used for R&D capacity (5%), market expansion (25%), general working capital (65%), and advisory fees (5%).
• The company operates a dual-class share structure, with Class B Ordinary Shares carrying 20 votes per share, giving the controlling shareholder, Mr. Ng Hon Kin, approximately 96.49% of total voting power post-IPO.
• The company is an 'emerging growth company' and 'foreign private issuer,' allowing for reduced reporting requirements.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including declining revenues, negative operating cash flows, and a 'going concern' warning from its auditors. While it has strategic growth plans and a loyal customer base, the macroeconomic headwinds in Hong Kong and intense competition pose substantial risks. The dual-class share structure also limits external shareholder influence. The IPO is critical for liquidity but comes with considerable uncertainties.

Positives

• Net income for the six months ended December 31, 2024, increased by 9.6% to $981,922 compared to $895,606 in the prior year period.
• The company boasts a high customer retention rate, with nearly 100% of its 2,600 unexpired prepaid package holders being repeat customers.
• Strategic plans include expanding geographical footprints in Southeast Asia, broadening service offerings to high-growth segments (e.g., male customers), and upgrading service technologies.
• The company maintains stringent quality control measures in supplier selection, treatment design, and service delivery, supported by regular inspections.
• Received the Enterprise Quality Service Award by the International Aestheticians Chamber of Commerce (INTACC) in 2019.
• Certified by Galderma and recognized as a Top Ten Sales Achievement Aesthetic Centre in Hong Kong for 2023 and 2024 for use of their products.
• The company's auditor, TAAD LLP, is based in California and subject to PCAOB regular inspection, mitigating some HFCAA risks.

Negatives

• Revenues decreased by 15.7% for the six months ended December 31, 2024, and by 24% for the year ended June 30, 2024, primarily due to weak economic conditions in Hong Kong, competition from Shenzhen, and customer emigration.
• Net income for the year ended June 30, 2024, significantly decreased by 68% to $607,678, largely due to increased audit fees and staff costs related to the IPO.
• The company has negative cash flows from operating activities for both the six months ended December 31, 2024 ($-611,480) and the year ended June 30, 2024 ($-1,031,834).
• Substantial working capital deficits of $8,313,163 as of December 31, 2024, and $9,029,519 as of June 30, 2024, raise 'substantial doubt' about the company's ability to continue as a going concern.
• The company is closing its Yuen Long shop due to customer loss to mainland China service providers, indicating regional competitive pressure.
• A dual-class share structure grants the controlling shareholder, Mr. Ng Hon Kin, approximately 96.49% of total voting power post-IPO, limiting influence for other shareholders.
• The company relies heavily on a single medical practitioner, Dr. Pang Sai Yau, for medical aesthetic services, posing a key person risk.
• The company's internal control over financial reporting has 'material weaknesses' due to limited accounting personnel and resources with U.S. GAAP and SEC reporting experience.

Risks

• Reputation in the industry is critical to success, and negative publicity or undesirable treatment outcomes could cause significant harm.
• Operating in a highly competitive industry with rapidly changing market trends, technological upgrades, and new treatments, where competitors may have more resources or better responsiveness.
• Demand for services is susceptible to changes in Hong Kong's economic conditions, as beauty services are discretionary items.
• A lack of qualified employees, particularly beauty and personal care professionals and medical practitioners, could hinder growth plans and adversely affect operations.
• Potential liability for malpractice of medical practitioners and negligence of staff members, with existing insurance policies not covering all liabilities.
• Increasingly stringent regulations on the medical aesthetic services industry in Hong Kong could impose significant compliance costs.
• The auditors have expressed 'substantial doubt' about the company's ability to continue as a going concern due to negative operating cash flows and significant working capital deficits.
• Inability to develop innovative services in a timely manner to meet changing customer preferences could adversely affect business.
• Limited control over the quality of beauty equipment and treatment devices, potentially leading to customer complaints and operational disruptions.
• Serious side effects from medical aesthetics procedures, though statistically insignificant, could lead to legal proceedings, liabilities, and reputational damage.
• Unfavorable public perception of the overall medical aesthetic services industry could reduce demand for services.
• The business has been materially and adversely affected by the COVID-19 pandemic, and future pandemics could have similar impacts.
• Reliance on the management team and key personnel, particularly Mr. Ng Hon Kin and Dr. Pang Sai Yau, poses a risk if their services are lost without suitable replacement.
• Expansion plans may not be commercially successful or achieve expected results, requiring substantial capital expenditure and financial resources.
• Failure to protect trade secrets and know-how or pursue infringement actions on intellectual properties could harm the business.
• Reliance on an internally designed database system (CARE) without timely backup or effective cybersecurity could adversely affect financial results.
• A downturn in the Hong Kong or global economy, or changes in economic and political policies of China, could materially and adversely affect business.
• Changes in Hong Kong government policies, regulations, and laws, or their enforcement, may be implemented quickly with little advance notice, impacting profitability.
• The PRC government may exercise significant oversight and discretion over business in Hong Kong, potentially intervening in operations or disallowing the organizational structure, which could cause the Class A Ordinary Shares to decline in value or become worthless.
• Funds or assets in Hong Kong subsidiaries may not be available for use outside Hong Kong due to PRC government interventions or restrictions on cash transfers, despite Hong Kong's lack of foreign exchange controls.
• Becoming subject to scrutiny, criticism, and negative publicity involving U.S.-listed Chinese companies could harm business operations, the offering, and reputation.
• Political risks associated with conducting business in Hong Kong, including the impact of the Hong Kong National Security Law and the HKAA, could adversely affect operations.
• Class A Ordinary Shares may be prohibited from trading in the United States under the HFCAA if the PCAOB is unable to inspect or investigate auditors located in Hong Kong for two consecutive years.
• Compliance with Hong Kong's Personal Data (Privacy) Ordinance and other data privacy laws may entail significant expenses and affect business.
• A cyberattack, security breach, or unauthorized access to IT systems could harm reputation and subject the company to significant liability.
• Uncertainty regarding the application of PRC laws and regulations on data security or overseas securities offerings to Hong Kong operations could significantly limit the ability to offer securities.
• An active trading market for Class A Ordinary Shares may not be established or continue, leading to potential illiquidity and price volatility.
• No expectation of paying dividends in the foreseeable future, requiring investors to rely on price appreciation for returns.
• New investors will experience immediate and substantial dilution due to the difference between the IPO price and net tangible book value per share.
• As a Cayman Islands exempted company and foreign private issuer, the company may adopt home country corporate governance practices that differ from Nasdaq rules, potentially offering less protection to shareholders.
• Difficulties in effecting service of legal process, enforcing foreign judgments, or bringing actions in Hong Kong against the company or management based on foreign laws.
• Stock price may be volatile and subject to rapid and substantial fluctuations unrelated to performance, especially with a small public float.
• If securities or industry analysts do not publish research or publish unfavorable or inaccurate research, the market price and trading volume could decline.
• The sale or availability for sale of substantial amounts of Class A Ordinary Shares could adversely affect their market price.
• Short selling may drive down the market price of Class A Ordinary Shares.
• Management has significant flexibility and discretion in using the net proceeds from the offering, which may not produce income or increase share price.
• More stringent criteria applied to emerging market companies by U.S. regulators could add uncertainties to the offering, business operations, share price, and reputation.

Future Outlook

The company intends to use IPO proceeds to expand market penetration in Southeast Asia, build R&D capacity for medical cosmetology technologies and products, further expand in existing markets, and meet general working capital needs. Management expects current operating results to be temporary and profitability to grow as Hong Kong's economy recovers. They plan to gradually restore the number of service centers to pre-COVID-19 levels and explore overseas markets like Malaysia and Singapore. The company will also broaden service offerings, including new treatments for male customers, and invest in software technology for real-time operations monitoring and data analytics.

Management Comments

• "Our value proposition is that we deliver quality aesthetics solutions tailored to the unique needs of each customer at competitive prices."
• "Our strategy is to differentiate ourselves by offering high-quality treatments and personalized services at a reasonable price instead of generic services at a discounted price."
• "We expect such operating results to be temporary and our profitability will grow as the city moves to its next economic cycle."
• "We believe that a public listing status will also enhance our corporate profile for the public and potential clients and investors."
• "Our mission is to be an industry leader in providing high-end medical cosmetology services and traditional facial or spa services."
• "We believe our customer base is crucial for the success of any business expansion."
• "We believe word of mouth is the most effective marketing channel, as returning customers may refer our services to their friends, family and work colleagues, and such referrals carry far greater weight to our target customers than paid advertisements."
• "Our management believes that we have sufficient capital resources to maintain our business operations for the next twelve months."

Industry Context

The global medical aesthetic services industry is projected to grow at an 11% CAGR from 2023 to 2028, driven by increased focus on personal appearance and rising demand for aesthetic procedures, particularly non-surgical ones. Hong Kong's beauty market, estimated at $2.45 trillion in 2023, is experiencing moderate growth, with medical cosmetic centers accounting for about 40%. However, the Hong Kong economy has been weak, leading to conservative consumer spending and increased competition from mainland China due to RMB depreciation. The industry also faces challenges from stringent regulations, liability risks, and competition from alternative products and home-use devices. The company's strategy to focus on high-end, personalized services and expand geographically aligns with the broader industry trend of seeking growth in specialized segments and new markets.

Comparison to Industry Standards

• The global medical aesthetic services industry is projected to expand at a CAGR of 11% from 2023 to 2028, while the Hong Kong beauty and personal care market is projected to grow at a CAGR of 1.9% between 2024 and 2028. MEDI Group's recent revenue decline (15.7% for 6 months ended Dec 2024, 24% for year ended June 2024) indicates underperformance relative to the broader industry growth trends.
• The company's net income margin for the year ended June 30, 2024, was 9.9%, a significant drop from 23.7% in the prior year, which may be below industry averages for specialized medical aesthetic services, especially considering the impact of IPO-related costs.
• The company's reliance on a single medical practitioner, Dr. Pang Sai Yau, for medical aesthetic services, while he is a 'pioneer' in the industry, presents a concentration risk that may be higher than larger, more diversified industry players.
• The company's 'going concern' warning and substantial working capital deficit are significant deviations from the financial health typically expected of a company undertaking an IPO, especially when compared to established industry benchmarks.
• The closure of the Yuen Long shop due to competition from mainland China highlights a specific regional challenge that may not be uniformly faced by all Hong Kong-based beauty service providers, particularly those with a more localized or less price-sensitive clientele.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of this prospectus, none of the company or its subsidiaries is a party to, nor has been threatened with, any legal proceeding that is likely to have a material adverse effect on its business, financial condition, or operations.

Related Party Transactions

• Mr. Ng Hon Kin, the Chairman, CEO, and ultimate shareholder, controls Global Medical Equipment Co., Ltd., Smart Key International Consultant Co., Ltd., and Be Health Co., Ltd., with which the company engages in transactions.
• Mr. Ng Hon Kin personally guaranteed all bank borrowings of the company, assuming these obligations from Ms. Huang Weisi on April 2, 2024.
• The company entered into a sub-lease agreement with Be Health Company Limited for a property in Yuen Long, with rental fees paid in aggregate of $30,366 for the six months ended December 31, 2024, and $61,107 for the eleven months ended May 31, 2025.
• A management agreement was entered into with Smart Key International Consultant Company Limited for administrative office lease, with management fees of $14,817 for the six months ended December 31, 2024, and $39,527 for the eleven months ended May 31, 2025.
• The company paid Smart Key International Consultant Company Limited $103,596 for management fees in the year ended June 30, 2024, and $618,963 in the year ended June 30, 2023.
• Equipment, materials, and services were purchased from Global Medical Equipment Co., Ltd. (nil for 6 months ended Dec 31, 2024; $4,157 for year ended June 30, 2024; $44,339 for year ended June 30, 2023).
• Equipment, materials, and services were purchased from Euro Cos Co., Ltd. ($212 for 6 months ended Dec 31, 2024; nil for year ended June 30, 2024; $463 for year ended June 30, 2023).
• Mr. Ng Hon Kin's salary and employee benefits were $8,091 for the six months ended December 31, 2024, and $15,385 for the year ended June 30, 2024, paid by an associated company.
• Promissory notes totaling $1,038,000 from seven individuals (including some selling shareholders) were converted into Ordinary Shares on March 28, 2024, at an issue price of $0.0001 per share.

Stakeholder Impact

• Shareholders: New investors will experience immediate and substantial dilution. The dual-class share structure significantly limits the voting power of Class A shareholders. The 'going concern' warning indicates a high risk of investment loss.
• Employees: The company plans to expand its beauty professional team, offering potential growth opportunities. However, the closure of the Yuen Long shop may impact some employees.
• Customers: The company aims to expand geographical footprints and broaden service offerings, potentially leading to more accessible and diverse services. The closure of the Yuen Long shop may inconvenience customers in that area.
• Suppliers: The company's financial health and operational changes could impact relationships with suppliers, though no immediate adverse effects are noted.
• Creditors: The 'going concern' warning and significant working capital deficit indicate increased risk for creditors, although the company intends to rely on IPO proceeds, bank borrowings, and shareholder loans for liquidity.

Next Steps

• Complete the initial public offering and list Class A Ordinary Shares on the Nasdaq Capital Market under the symbol MEDG.
• Close the Yuen Long shop by September 30, 2025, and open a new shop in another location in Hong Kong.
• Set up research and development capacity for medical cosmetology technologies, services, and products.
• Penetrate and further expand into new and existing geographical markets, including exploring Southeast Asia (Malaysia and Singapore).
• Broaden service offerings to cater to high-growth segments, such as male customers, and introduce new skin care regimens.
• Recruit, train, and maintain a team of experienced management and senior beauty professionals, aiming to expand to three medical practitioners and 40 therapists.
• Invest in software technology for real-time operational monitoring, centralized information exchange, and data analytics.
• Ms. Kelly Sin Pui Ying will assume the role of Chief Financial Officer from September 15, 2025.

Key Dates

Recommendation

The company presents a high-risk investment profile. Significant financial declines in revenue, persistent negative operating cash flows, and a substantial working capital deficit, coupled with an explicit 'going concern' warning from auditors, indicate severe underlying business challenges. While the IPO aims to address liquidity, the macroeconomic headwinds in Hong Kong, intense competition, and the inherent risks of a dual-class share structure (concentrating control) make the investment highly speculative. The immediate and substantial dilution for new investors further detracts from its appeal. A seasoned investor would likely view these factors as strong indicators to avoid or sell, given the high probability of capital loss and the lack of clear, immediate pathways to sustainable profitability.

Keywords

Medical Cosmetology, Beauty Services, Hong Kong, SEC F-1, IPO, Nasdaq Listing, Dual-Class Shares, Going Concern, Risk Factors, Financial Performance, Corporate Governance, PRC Regulation, Data Privacy, HFCAA